Business
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 - Conference Call to Follow
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ...
About this update from Profound Medical Corp
[{"type":"text","content":"Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow\n\n\n\n TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) --\n \n\n Profound Medical Corp.\n \n\n (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.\n \n\n Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.\n \n\n\n Fourth Quarter and Full Year 2024 Results Conference Call Details:\n \n\n\n Date: Thursday, March 6, 2025\n \n\n Time: 4:30 p.m. ET\n \n\n Live Call Registration:\n \n\n https://register.vevent.com/register/BI4fc1c4c3061645ca9f513f8f017abfbb\n \n\n\n\n The call will also be broadcast live and archived on the Company's website at\n \n\n www.profoundmedical.com\n \n\n under “Webcasts” in the Investors section.\n \n\n\n About Profound Medical Corp.\n \n\n\n Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.\n \n\n Profound is commercializing TULSA-PRO\n \n ®\n \n , a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO\n \n ®\n \n system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that...